<DOC>
	<DOCNO>NCT00085566</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell stop blood flow tumor . Gefitinib may stop growth tumor cell block enzymes necessary growth . Combining everolimus gefitinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose everolimus give together gefitinib see well work treat patient progressive glioblastoma multiforme ( progressive metastatic prostate cancer close accrual 10/19/06 ) .</brief_summary>
	<brief_title>Everolimus Gefitinib Treating Patients With Progressive Glioblastoma Multiforme Progressive Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose everolimus give combination gefitinib patient progressive glioblastoma multiforme ( progressive castrate metastatic prostate cancer -closed accrual 10/19/2006 ) . ( Phase I ) - Determine safety efficacy regimen patient progressive glioblastoma multiforme ( progressive castrate metastatic prostate cancer - close accrual 10/19/2006 ) . ( Phase II ) Secondary - Determine whether pharmacokinetic interaction exist everolimus gefitinib patient treat regimen . - Determine association clinical outcome marker may predict sensitivity tumor patient treat regimen . - Determine pharmacodynamic effect regimen post-therapy tumor specimens peripheral blood mononuclear cell patient . OUTLINE : This phase I , open-label , non-randomized , dose-escalation study everolimus follow phase II study . - Phase I : Patients receive oral everolimus day 1 oral gefitinib daily day 8-21 . Beginning day 22 , patient receive oral everolimus weekly oral gefitinib daily . Treatment combination continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos everolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II ( prostate cancer patient ) ( close accrual 10/19/2006 ) : Patients receive oral everolimus ( MTD determine phase I ) weekly oral gefitinib daily . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Glioblastoma multiforme ( GBM ) ( phase I ) Progressive disease despite standard therapy Progressive disease base 1 follow : New progressive ( 25 % bidimensional increase ) soft tissue mass CT scan MRI New prior lesion increase size physical examination Patients prior interstitial brachytherapy stereotactic radiosurgery must confirmation true disease progression ( rather radiation necrosis ) positronemission tomography scan , thallium scanning , magnetic resonance spectroscopy , surgical documentation Castrate metastatic prostate cancer ( close accrual 10/19/2006 ) ( phase I II ) Progressive disease despite standard therapy AND castrate level &lt; 50 ng/dL testosterone Progressive disease base 1 follow : A minimum 3 rising level prostatespecific antigen ( PSA ) obtain 1 week apart OR 2 rise PSA value obtain 1 month apart least 25 % increase range value New progressive ( 25 % bidimensional increase ) soft tissue mass CT scan MRI New metastatic lesion Patients antiandrogen part initial therapy must show disease progression discontinuation antiandrogen Patients undergone surgical orchiectomy must continue medical therapy ( e.g. , gonadotropinreleasing hormone analog ) maintain castrate level serum testosterone No brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 70100 % Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic ALT AST ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 mg/dL Renal Creatinine within 1.5 time ULN ( &lt; 1.95 mg/dL MSKCC ) Cardiovascular No significant cardiovascular disease No congestive heart failure No New York Heart Association class III IV cardiac disease No active angina pectoris No myocardial infarction within past 6 month Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No serious medical illness No severe infection No severe malnutrition No active malignancy except nonmelanoma skin cancer Patients consider active malignancy complete prior therapy currently &lt; 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biological therapy No concurrent immunotherapy Chemotherapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Prior recent resection recurrent progressive GBM allow provide patient recover More 4 week since prior major surgery Other Recovered prior therapy More 4 week since prior investigational anticancer drug No concurrent anticonvulsant interacts CYP3A4 ( e.g. , phenytoin , carbamazepine , phenobarbital ) No concurrent cytotoxic therapy No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>